BPC-157 (Body Protection Compound-157)
BPC-157 is a synthetic peptide derived from a naturally occurring protein found in gastric (stomach) juice. It consists of 15 amino acids and has been studied for its regenerative and protective properties. Research, primarily in animal models, suggests it may accelerate healing of tissues including muscles, tendons, ligaments, and the gastrointestinal tract. It is sometimes referred to as a “stable gastric pentadecapeptide” due to its origin and structure.
How It Is Used In Research Settings
- Angiogenesis stimulation: Promotes the formation of new blood vessels, improving nutrient and oxygen delivery to injured tissues.
- Collagen production: Enhances fibroblast activity and collagen synthesis, which are critical for tendon and ligament repair.
- Anti-inflammatory action: Reduces pro-inflammatory cytokines and supports a balanced healing environment.
- Gastrointestinal protection: Protects and promotes healing of the gut lining in models of ulcers, colitis, and other GI injuries.
- Neuroprotection: Early research suggests potential protective effects on the nervous system after injury.
Proposed Uses (Research Areas)
- Muscle, tendon, and ligament healing: Accelerates recovery from sports injuries and connective tissue damage.
- Joint protection: Studied for its ability to reduce joint inflammation and improve function after damage.
- Gut health: Shown to help heal ulcers, protect intestinal lining, and reduce symptoms of inflammatory bowel conditions in animal models.
- Nerve repair: Preliminary studies indicate possible benefits in peripheral nerve injury recovery.
- Wound healing: Improves angiogenesis and tissue remodeling in skin and soft tissue wounds.
Typical Research Dosages
Human clinical dosing has not been standardized, but animal studies and anecdotal reports from research settings have informed the following ranges:
- Injectable (subcutaneous or intramuscular near the injury site): 200–500 mcg daily, often continued for 2–4 weeks. Some protocols use up to 1,000 mcg per day depending on severity of injury.
- Oral formulations: Capsules or solutions at 250–500 mcg daily are sometimes used, though oral bioavailability is less well documented.
- Cycle length: Most reported protocols run for 2–6 weeks, with adjustments based on the type of injury or condition being studied.
Important Considerations
- Regulatory status: BPC-157 is not FDA-approved as a therapeutic drug. Its use is restricted to research contexts in most countries.
- Evidence base: The majority of data comes from animal studies. Human clinical trials are lacking, so translation of results to people remains uncertain.
- Safety: Generally well tolerated in research studies, but long-term safety in humans is unknown. Sourcing and purity remain concerns when purchased outside regulated environments.
Disclaimer:
This information is provided for educational purposes only. It is a summary of published research on BPC-157 and is not intended as medical advice. BPC-157 is considered experimental in most contexts and should not be viewed as an approved therapy for medical use.
This peptide is for research use only.